Analysis
T-Therapeutics has raised $133 million in an oversubscribed Series B, co-led by Advent Life Sciences and the British Business Bank, to push two T cell receptor (TCR) therapy programs through early clinical trials, the Cambridge, UK-based biotech said, according to Pulse 2.0. The round brings in new backers including Johnson & Johnson Innovation, Samsara BioCapital, Merck KGaA's M Ventures and Eli Lilly and Company, alongside existing investors Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, Tencent and BGF.
What T-Therapeutics does
T-Therapeutics develops TCR-based therapies for cancer and autoimmune disease using a proprietary platform it calls OpTiMus, designed to generate fully human T cell receptors against disease-related proteins that conventional antibody drugs struggle to target. The company's pipeline centers on two first-in-class TCR-CD3 bispecific programs: a lead oncology candidate aimed at solid tumors, and an immunology program designed to eliminate the disease-causing cells behind chronic inflammatory conditions. CEO Theodora Harold said the new capital is "a key step in our transition to a clinical-stage company," with proceeds funding both programs through clinical proof-of-concept milestones.
T-Therapeutics funding history
T-Therapeutics has not disclosed the size of its prior funding rounds, though its existing investor base -- Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, Tencent and BGF -- points to multiple earlier rounds before this Series B, which adds to 2026's run of biotech mega-raises tracked in our funding tracker. What's new this time is the addition of four strategic and growth investors in a single oversubscribed close, a sign of broader pharma interest in TCR-based approaches than the company's cap table alone previously reflected.
“Advent Life Sciences and the British Business Bank co-led the round.”
Who invested in T-Therapeutics
Advent Life Sciences and the British Business Bank co-led the round. Dominic Schmidt, general partner at Advent Life Sciences, said "T cell engagers have delivered clinical success in hematological cancers," framing the firm's bet on T-Therapeutics' solid-tumor and immunology programs as an extension of that validated mechanism into harder indications. New participants Johnson & Johnson Innovation, Samsara BioCapital, M Ventures and Eli Lilly and Company will each place a representative on T-Therapeutics' board as non-executive directors, alongside Advent and the British Business Bank. The company also added Dr. Kirsty Crame as chief development officer; she joins from Curatis, where she was chief medical officer, with earlier clinical-development roles at Medigene and Gadeta, and called it "a pivotal moment for the Company."
TCR therapy market and competitors
T-Therapeutics is entering a field that only recently produced its first approved product: Adaptimmune's Tecelra became the first FDA-approved engineered cell therapy for a solid tumor in August 2024, winning accelerated approval for synovial sarcoma based on a 43% overall response rate in the 44-patient SPEARHEAD-1 trial, according to FiercePharma. That approval validated TCR-based attacks on solid tumors as clinically possible, but Adaptimmune's own stock has traded near $1 since, a fraction of its IPO price -- a reminder of how far commercial validation still lags scientific validation in this category. T-Therapeutics' bet on TCR-CD3 bispecifics, rather than Adaptimmune's cell-therapy approach, sits alongside Immatics and other TCR-focused biotechs chasing the same solid-tumor opportunity Tecelra opened but has not yet proven commercially durable.
What to watch next
T-Therapeutics has not disclosed clinical trial timelines or specific proof-of-concept readout dates for either program, so the near-term catalyst to watch is simply whether the oncology or immunology candidate reaches the clinic first. The company's bet -- that fully human TCRs can succeed where solid-tumor immunotherapy has repeatedly fallen short -- remains unproven until that first clinical data reads out, oversubscribed round or not.